PTC Therapeutics (PTCT) CLO exercises options and sells 2,812 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and CLO, exercised stock options for 2,812 shares of Common Stock at $25.69 per share and, on the same date, sold 2,812 shares in open-market transactions at weighted average prices of $72.67 and $72.08. These trades were made under a pre-arranged Rule 10b5-1 plan. Following the transactions, he directly holds 105,212 Common Stock shares and 19,689 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,812 shares ($202,958)
Net Sell
4 txns
Insider
Boulding Mark Elliott
Role
EXEC. VP AND CLO
Sold
2,812 shs ($203K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,812 | $0.00 | -- |
| Exercise | Common Stock | 2,812 | $25.69 | $72K |
| Sale | Common Stock | 2,356 | $72.08 | $170K |
| Sale | Common Stock | 456 | $72.67 | $33K |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,689 shares (Direct, null);
Common Stock — 108,024 shares (Direct, null)
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.41 to $72.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.41 to $72.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Key Figures
Shares sold: 2,812 shares
Sale prices: $72.67 and $72.08 per share
Option exercise price: $25.69 per share
+5 more
8 metrics
Shares sold
2,812 shares
Open-market sales of Common Stock on May 15, 2026
Sale prices
$72.67 and $72.08 per share
Weighted average sale prices for two sale blocks
Option exercise price
$25.69 per share
Conversion price for exercised stock option
Common shares after trades
105,212 shares
Direct Common Stock holdings following transactions
Options remaining
19,689 options
Stock options outstanding after the reported exercise
Rule 10b5-1 plan adoption date
September 10, 2025
Date trading plan governing sales was adopted
Option grant date
February 15, 2024
Grant date of the exercised stock option
Option expiration
February 14, 2034
Expiration date of the underlying stock option grant
Key Terms
Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), vests over four years, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vests over four years financial
"This option was granted on February 15, 2024, and vests over four years"
A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transactions did PTCT executive Mark Elliott Boulding report?
Mark Elliott Boulding reported exercising options for 2,812 PTCT shares and selling 2,812 shares in open-market trades. The activity combined an option exercise at a lower strike price with same-day sales at higher market prices.
What stock option exercise did the PTCT Form 4 disclose for Mark Elliott Boulding?
The Form 4 shows Boulding exercised a stock option for 2,812 PTCT Common Stock shares at a conversion price of $25.69 per share. This option was part of a grant made on February 15, 2024, that vests quarterly over four years.
What are the vesting terms of Mark Elliott Boulding’s PTCT stock option grant?
The option was granted on February 15, 2024, with 25% vesting on February 15, 2025. An additional 6.25% of the original option shares vest at the end of each three-month period starting May 15, 2025, over four years.